Share on

In this video, IMF Chairman Brian G.M. Durie moderates a discussion with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Philippe Moreau (University of Nantes - Nantes, France) about new agents for multiple myeloma, such as CAR T-cell therapies, AMG 420 BiTE, and CELMoD (CC220).

This video is the fifth in a five-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from the American Society of Clinical Oncology (ASCO) and the International Myeloma Working Group 2019 Summit.

Download Slides

Topics Covered:


Thank you to our sponsors:
Takeda Oncology

 

Previous Post
Relapse Therapies
Next Post
Multiple Myeloma Background, Shared Decision Making, and Smoldering MM Research Update

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.